<table id="table7" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 7: Effect of Other Drugs on Voriconazole Pharmacokinetics [see <linkhtml href="#s12.3">Clinical Pharmacology (12.3)</linkhtml>]</caption>
<col align="left" valign="top" width="33%"></col>
<col align="center" valign="top" width="33%"></col>
<col align="center" valign="top" width="34%"></col>
<thead>
<tr>
<th align="center" stylecode="Lrule">Drug/Drug Class<br/>(Mechanism of  Interaction by the Drug)</th>
<th stylecode="Lrule">Voriconazole Plasma  Exposure<br/>(C<sub>max</sub> and AUC<sub>τ</sub> after<br/>200 mg q12h)</th>
<th stylecode="Lrule Rrule">Recommendations for  Voriconazole Dosage Adjustment/Comments</th>
</tr>
</thead>
<tbody>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Rifampin<footnote id="t7f1">Results based on <content stylecode="italics">in vivo</content> clinical studies generally following repeat oral dosing with 200 mg q12h voriconazole to healthy subjects</footnote> and Rifabutin<footnoteref idref="t7f1"></footnoteref>
<br/>(CYP450 Induction)</td>
<td stylecode="Rrule">Significantly Reduced</td>
<td stylecode="Rrule">
<content stylecode="bold">Contraindicated</content>
</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Efavirenz (400 mg q24h)<footnote id="t7f2">Results based on <content stylecode="italics">in </content>
<content stylecode="italics">vivo</content> clinical study following repeat oral dosing with 400 mg q12h for 1 day, then 200 mg q12h for at least 2 days voriconazole to healthy subjects</footnote>
<br/>(CYP450 Induction)</td>
<td stylecode="Rrule">Significantly Reduced</td>
<td stylecode="Rrule">
<content stylecode="bold">Contraindicated</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Efavirenz (300 mg q24h)<footnoteref idref="t7f2"></footnoteref>
<br/>(CYP450 Induction)</td>
<td stylecode="Rrule">Slight Decrease in AUC<content stylecode="bold">
<sub>τ</sub>
</content>
</td>
<td stylecode="Rrule">When voriconazole is coadministered with efavirenz, voriconazole oral maintenance dose should be increased to 400 mg q12h and efavirenz should be decreased to 300 mg q24h</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">High-dose Ritonavir (400 mg q12h)<footnoteref idref="t7f2"></footnoteref> (CYP450 Induction)</td>
<td stylecode="Rrule">Significantly Reduced</td>
<td stylecode="Rrule">
<content stylecode="bold">Contraindicated</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Low-dose Ritonavir (100 mg q12h)<footnoteref idref="t7f2"></footnoteref> (CYP450 Induction)</td>
<td stylecode="Rrule">Reduced</td>
<td stylecode="Rrule">Coadministration of voriconazole and low-dose ritonavir (100 mg q12h) should be avoided, unless an assessment of the benefit/risk to the patient justifies the use of voriconazole</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Carbamazepine<br/>(CYP450 Induction)</td>
<td stylecode="Rrule">Not Studied <content stylecode="italics">In Vivo</content> or <content stylecode="italics">In Vitro</content>, but Likely to Result in Significant Reduction</td>
<td stylecode="Rrule">
<content stylecode="bold">Contraindicated</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Long Acting Barbiturates<br/>(CYP450 Induction)</td>
<td stylecode="Rrule">Not Studied <content stylecode="italics">In Vivo</content> or <content stylecode="italics">In Vitro</content>, but Likely to Result in Significant Reduction</td>
<td stylecode="Rrule">
<content stylecode="bold">Contraindicated</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Phenytoin<footnoteref idref="t7f1"></footnoteref>
<br/>(CYP450 Induction)</td>
<td stylecode="Rrule">Significantly Reduced</td>
<td stylecode="Rrule">Increase voriconazole maintenance dose from 4 mg/kg to 5 mg/kg IV q12h or from 200 mg to 400 mg orally q12h (100 mg to 200 mg orally q12h in patients weighing less than 40 kg)</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">St. John's Wort<br/>(CYP450 inducer; P-gp inducer)</td>
<td stylecode="Rrule">Significantly Reduced</td>
<td stylecode="Rrule">
<content stylecode="bold">Contraindicated</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Oral Contraceptives<footnoteref idref="t7f2"></footnoteref>
<br/>containing ethinyl estradiol and norethindrone (CYP2C19 Inhibition)<br/>
</td>
<td stylecode="Rrule">Increased</td>
<td stylecode="Rrule">Monitoring for adverse events and toxicity related to voriconazole is recommended when coadministered with oral contraceptives</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Fluconazole<footnoteref idref="t7f2"></footnoteref> (CYP2C9, CYP2C19 and CYP3A4 Inhibition)</td>
<td stylecode="Rrule">Significantly Increased</td>
<td stylecode="Rrule">Avoid concomitant administration of voriconazole and fluconazole. Monitoring for adverse events and toxicity related to voriconazole is started within 24 h after the last dose of fluconazole.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Other HIV Protease Inhibitors<br/>(CYP3A4 Inhibition)</td>
<td stylecode="Rrule">
<content stylecode="italics">In Vivo</content> Studies Showed No Significant Effects of Indinavir on Voriconazole Exposure</td>
<td stylecode="Rrule">No dosage adjustment in the voriconazole dosage needed when coadministered with indinavir</td>
</tr>
<tr>
<td stylecode="Lrule Rrule"> </td>
<td stylecode="Rrule"> </td>
<td stylecode="Rrule"> </td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule"></td>
<td stylecode="Rrule">
<content stylecode="italics">In Vitro</content> Studies Demonstrated Potential for Inhibition of Voriconazole Metabolism (Increased Plasma Exposure)</td>
<td stylecode="Rrule">Frequent monitoring for adverse events and toxicity related to voriconazole when coadministered with other HIV protease inhibitors<br/>
</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Other NNRTIs<footnote>Non-Nucleoside Reverse Transcriptase Inhibitors</footnote>
<br/>(CYP3A4 Inhibition or CYP450 Induction)</td>
<td stylecode="Rrule">
<content stylecode="italics">In Vitro</content> Studies Demonstrated Potential for Inhibition of Voriconazole Metabolism by Delavirdine and Other NNRTIs (Increased Plasma Exposure)</td>
<td stylecode="Rrule">Frequent monitoring for adverse events and toxicity related to voriconazole</td>
</tr>
<tr>
<td stylecode="Lrule Rrule"> </td>
<td stylecode="Rrule"> </td>
<td stylecode="Rrule"> </td>
</tr>
<tr>
<td stylecode="Lrule Rrule"></td>
<td stylecode="Rrule">A Voriconazole-Efavirenz Drug Interaction Study Demonstrated the Potential for the Metabolism of Voriconazole to be Induced by Efavirenz and Other NNRTIs<br/>(Decreased Plasma Exposure)<br/>
</td>
<td stylecode="Rrule">Careful assessment of voriconazole effectiveness</td>
</tr>
</tbody>
</table>